A statement of purpose — what we are building, who it is for, and what we will never claim to be.
Longevity medicine is moving faster than any physician can track manually. Geroevidence exists to close that gap — without hype, without commercial interests, and without pretending the evidence is stronger than it is.
A physician practicing longevity medicine in 2026 is trying to stay current across rapamycin, metformin, GLP-1 agonists, SGLT2 inhibitors, senolytics, NAD+ precursors, and a dozen other compounds — each with its own trial pipeline, evidence base, and rapidly evolving literature.
The information available to them comes from three sources — each with serious problems.
Podcasts and media. Fast, accessible, and often ahead of the literature. Also prone to overstating emerging evidence, confusing mechanistic plausibility with clinical proof, and being influenced by the commercial interests of guests and sponsors.
PubMed and ClinicalTrials.gov. Authoritative and primary. Also overwhelming. A physician who wants to know the current evidence for rapamycin would need to read dozens of papers, assess study quality, and synthesize across conflicting results — every week, across every intervention in their practice.
Existing clinical decision support tools. Built for disease management not longevity. UpToDate covers rapamycin for transplant rejection. It does not cover the PEARL trial, the ITP mouse data, or the current evidence for off-label longevity use.
Geroevidence is a clinical evidence reference service. We index published research, grade it on a four-tier evidence ladder, and surface updates when the evidence changes. Every claim links to a primary source. Every profile is reviewed before it publishes. Every evidence tier is assigned honestly — Emerging evidence is not promoted to Moderate because a compound is popular.
We are built for the small number of physicians who are already practicing at the frontier of geroscience — who already read the trials, who already understand the difference between a surrogate endpoint and a hard outcome, and who want a synthesis layer that keeps them current without requiring them to read every paper themselves.
We will never tell you what to prescribe. We will never tell you what dose to use. We will never tell a patient what to take. The boundary between evidence synthesis and clinical recommendation is one we will not cross — because crossing it would require us to know your patient, which we do not.
We will never accept advertising, sponsored content, or payment from any company with a commercial interest in the compounds we cover. The longevity supplement industry has enormous financial incentives to overstate the evidence. We have no such incentive — our only product is accurate synthesis.
We will never promote evidence beyond what it supports. When the evidence is Emerging, we will say Emerging. When a trial uses surrogate endpoints, we will say so. When a positive animal study has not been replicated in humans, we will say so. The physicians who use Geroevidence are sophisticated enough to handle honest uncertainty — and are better served by it than by false confidence.
Longevity medicine in 2026 is a field where the scientific rationale is frequently ahead of the clinical evidence. The hallmarks of aging are well characterized. The biological mechanisms of the most promising interventions are coherent and increasingly well understood. The hard clinical outcomes trials — with longevity or healthspan as primary endpoints, in healthy aging populations, with adequate follow-up — are either in progress or not yet started.
That gap between mechanism and evidence is not a failure of the field. It is the honest current state of a young science. Geroevidence will track both — the emerging science and the evolving evidence — and will update the record as the trials report. We are a living reference, not a static textbook. The evidence changes. We change with it.